AXON
Closed
Axovant Sciences Ltd
775.38
-52.56 (-6.35%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 827.94
Day's Range: 765.5 - 829.5
Send
sign up or login to leave a comment!
When Written:
224.85
Axovant Sciences Ltd is a biopharmaceutical company that focuses on developing innovative therapies for neurological disorders. The company was founded in 2014 and is headquartered in London, UK, with additional offices in New York, USA, and Basel, Switzerland.
Axovant Sciences is primarily focused on developing gene therapies and small molecule drugs for the treatment of Alzheimer’s disease and other forms of dementia. The company’s lead product candidate, RVT-101, is a small molecule drug that targets the 5-HT6 receptor in the brain, which is believed to play a role in cognitive function.
Axovant Sciences has also developed a gene therapy platform called AXO-Lenti-PD, which is designed to deliver a gene therapy for Parkinson’s disease. The company is currently conducting clinical trials of this therapy.
In 2020, Axovant Sciences merged with a privately-held gene therapy company, Benitec Biopharma. The merged company is now known as Axovant Gene Therapies Ltd and is focused on advancing gene therapies for neurological disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Axovant Sciences is primarily focused on developing gene therapies and small molecule drugs for the treatment of Alzheimer’s disease and other forms of dementia. The company’s lead product candidate, RVT-101, is a small molecule drug that targets the 5-HT6 receptor in the brain, which is believed to play a role in cognitive function.
Axovant Sciences has also developed a gene therapy platform called AXO-Lenti-PD, which is designed to deliver a gene therapy for Parkinson’s disease. The company is currently conducting clinical trials of this therapy.
In 2020, Axovant Sciences merged with a privately-held gene therapy company, Benitec Biopharma. The merged company is now known as Axovant Gene Therapies Ltd and is focused on advancing gene therapies for neurological disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!